Modified Chimeric antigen receptor T cells elicited anti-tumor activity in cancer patients who have not responded to prior treatments, a new study showed. CAR T cells were altered to recognize the protein mesothelin in tumor cells using mRNA and were infused back intravenously in two cancer patients, which resulted in a stabilized condition and a decrease in the number of tumor cells, according to the study in Cancer Immunology Research. "We found that these CARTmeso cells not only have anti-tumor activity, but also act like a vaccine, and trigger a response against the patient's own tumor," said lead study author Dr. Carl H. June.

Related Summaries